AAV Application in Cancer: From Precision Tools to Gene Therapy Vectors

Gene therapy is undergoing a fundamental expansion from rare genetic diseases into complex, multifactorial conditions such as cancer. Among available delivery systems, Adeno-Associated Virus (AAV) has emerged as a uniquely adaptable platform, combining a strong safety profile, long-term gene expression, and compatibility with advanced genetic engineering technologies. Although AAV was initially defined by its role in monogenic disease correction, recent advances in capsid engineering, synthetic biology, and immuno-oncology are rapidly broadening its relevance in oncology.

Cancer poses a fundamentally different challenge from inherited disorders. Tumors are heterogeneous, dynamically evolving, and deeply shaped by a complex microenvironment that includes immune cells, stromal cells, and vascular networks. In this context, AAV-based strategies must go far beyond simple gene replacement. They in fact become the more sophisticated therapeutic platforms capable of correcting cancer-associated genetic defects, reprogramming the tumor microenvironment, and eliciting more effective anti-tumor immune responses. At the same time, AAV vectors continue to serve as powerful research tools, enabling the development of clinically relevant disease models and the delivery of precision gene-editing machinery. Together, these advances are driving a new generation of AAV applications in cancer that is mechanistically diverse, increasingly sophisticated, and potentially transformative for both research and therapy.

In this article, we present a framework for categorizing AAV applications in cancer, highlighting the underlying mechanisms, key advantages, and recent innovations within each area, while also providing the latest industry updates and selected AACR 2026 abstracts to watch.

AAV Application in Cancer

A. Gene Replacement and Functional Gene Supplementation

At the fundamental level, AAV can restore proteins lost through mutation or deletion, or supplement therapeutic genes that inhibit tumor progression. This strategy is especially relevant in monogenic tumor-predisposition syndromes and in cancers driven by well-defined genetic lesions. By delivering a functional, truncated, or rationally engineered version of a tumor suppressor, AAV can re-establish critical signaling pathways that were disrupted during tumorigenesis.

A notable study on NF1-related tumors highlights a common technical hurdle: the native NF1 gene is too large for standard AAV packaging capacity. To overcome this limitation, researchers engineered a compact transgene containing the key GAP-related domain of neurofibromin, enabling partial but functionally meaningful restoration of RAS regulation. Delivery of this mini-gene via AAV suppressed tumor growth in preclinical models, demonstrating that full-length replacement is not always necessary for therapeutic benefit. More broadly, this illustrates a growing trend in AAV oncology: functional modularization of large genes so that essential biological activity can be preserved within vector size constraints.

AAV Capsid engineering further strengthens this approach by improving tumor tropism and reducing off-target sequestration, particularly in the liver. In some settings, this creates a markedly improved therapeutic index. In ovarian cancer, for example, AAV-mediated supplementation of anti-angiogenic or immune-modulatory factors has shown promise for achieving long-term local control. Unlike transient non-viral delivery systems, AAV can provide sustained expression, supporting durable suppression of tumor growth and metastasis while minimizing systemic toxicity.

B. Precision Gene Editing and Genome Engineering

Building directly on gene replacement, AAV is also becoming an important delivery platform for precision genome editing technologies, including CRISPR-Cas nucleases, base editors, and prime editors. In this setting, AAV is used not merely to add a gene, but to directly modify the cancer genome or reprogram genetically defined resistance pathways.

These approaches make it possible to correct oncogenic mutations, knock out driver genes, restore defective tumor suppressor pathways, or sensitize tumors to radiation or targeted therapy. Dual-AAV systems help address the packaging challenge posed by large editing cargos, allowing otherwise oversized editing components to be delivered in vivo. Base editing is especially attractive because it can reverse disease-relevant point mutations while minimizing double-strand breaks and unwanted indels, and prime editing further expands the range of correctable mutations.

Beyond therapeutic correction, AAV-delivered editing systems are also powerful tools for cancer modeling and target validation. By introducing specific mutations, activating oncogenes, or deleting tumor suppressors directly in vivo, researchers can create models that more closely mimic human tumor evolution. This makes AAV valuable not only as a therapeutic modality, but also as a research platform for identifying dependencies, studying progression, and validating drug responses. The research and therapeutic uses of AAV genome engineering are closely linked: the same delivery capabilities that enable functional tumor modeling may also support future clinical editing strategies.

C. Immune Modulation and Tumor Microenvironment Remodeling

One of the most transformative roles of AAV in oncology lies in its ability to reprogram the tumor microenvironment (TME). Many solid tumors remain immunologically “cold,” with poor T-cell infiltration and strong local immunosuppression. AAV vectors can overcome this by delivering cytokines, chemokines, or co-stimulatory ligands directly into tumors, thereby converting the tumor site into a sustained source of immune activation.

This strategy is particularly powerful because AAV enables localized and prolonged expression of immune-active molecules such as IL-10, IL-12, or 4-1BBL, avoiding many of the limitations of systemic cytokine therapy. Rather than producing short-lived systemic exposure with substantial toxicity, AAV allows these potent molecules to act directly within the tumor or tumor-bearing organ. The downstream effects can include enhanced antigen presentation, recruitment and activation of cytotoxic T cells, increased production of effector cytokines, and conversion of an immunosuppressive environment into a pro-inflammatory one.

Recent work in hepatocellular carcinoma and glioblastoma has shown that AAV-mediated cytokine delivery can significantly boost anti-tumor immunity, including the formation of durable tissue-resident memory-like CD8⁺ T-cell populations.  AAV is particularly well suited for in situ immunotherapy, where the tumor itself becomes a controlled site of immune activation.

D. Precision-Controlled Expression and Synthetic Regulatory Systems

A major limitation of earlier gene therapy strategies was the inability to control where and when therapeutic genes were expressed. In oncology, this is especially problematic because systemic or ectopic expression of cytokines or cytotoxic factors can lead to severe toxicity. Synthetic biology is now helping solve this problem by equipping AAV vectors with tumor-responsive regulatory systems.

These include interferon-responsive promoters, radiation-inducible systems, and synthetic super-enhancers (SSEs) assembled from validated enhancer modules that are active in specific malignant cell states. In glioblastoma, for example, SSEs based on SOX2- and SOX9-driven transcriptional programs have been used to drive high-level expression selectively in glioblastoma stem cells while remaining largely inactive in surrounding normal cells. This level of selectivity enables AAV to function as a context-aware therapeutic platform, capable of delivering immunomodulatory or cytotoxic payloads only under defined biological conditions.

When coupled with cytotoxic genes such as HSV-TK and immune stimulators such as IL-12, these regulatory systems create a highly sophisticated form of precision viral immunotherapy. The advantage is not simply stronger expression, but safer expression, with a substantially improved therapeutic window compared with constitutive promoters.

E. Combination Strategies with Radiotherapy and Other Modalities

The most advanced AAV cancer applications increasingly combine vector delivery with radiotherapy, immunotherapy, or other treatment modalities. In some cases, radiotherapy directly enhances AAV activity by remodeling chromatin and increasing transgene expression from AAV episomes. This creates an opportunity to use radiation not only as a cytotoxic modality, but also as a biological trigger for AAV-based therapies.

When AAV vectors carrying IFN-inducible cytokine payloads are paired with radiotherapy, the irradiated tumor becomes a highly localized site of transgene activation. In effect, radiation can convert the tumor into an in situ vaccine, with AAV providing spatially confined immune stimulation. These approaches have shown the ability to generate both local and systemic anti-tumor immunity while overcoming common immune-evasion mechanisms such as checkpoint upregulation, myeloid suppression, and T-cell exclusion.

More broadly, such multimodal strategies reflect how AAV is increasingly functioning not in isolation, but as an adaptable component within combination regimens that integrate gene delivery, radiation, and immune modulation (Table 1).

Summary of Recent Scientific Literature and Industry Update

Development of an AAV Vector for Gene Replacement Therapy of NF1-Related Tumors
In a Nature Communications study, Bai et al. addressed two major barriers to using AAV gene therapy for NF1-associated tumors: the large size of the native NF1 gene, which exceeds standard AAV packaging capacity, and the limited ability of natural AAV serotypes to efficiently target NF1 tumors. To overcome these challenges, the authors combined AAV transgene engineering with AAV capsid engineering, creating both a compact therapeutic miniNF1 construct and a novel tumor-tropic AAV capsid optimized for NF1 tumor delivery.

Their approach relied on advanced AAV vector engineering at two levels. First, they designed GRDC24, a miniNF1 transgene containing the GAP-related domain fused to the KRAS4B membrane-targeting domain, allowing the therapeutic cassette to fit within the size constraints of an AAV vector while preserving key biological function. Second, they used directed evolution of AAV capsids, beginning with DNA shuffling across 12 natural AAV serotypes, followed by in vivo selection in MPNST xenograft models. A second round of AAV library screening introduced random 7-mer peptides into the AAV capsid VR-VIII loop to further refine tumor targeting. This process ultimately yielded AAV-K55, a newly evolved AAV vector with enhanced tropism for NF1 tumors. The resulting AAV platform was then evaluated in orthotopic xenograft and patient-derived tumor models.

The resulting AAV-based NF1 therapy showed strong promise. AAV-K55 achieved approximately 30–60% tumor transduction across multiple NF1 tumor models and, importantly, showed substantially lower liver uptake than AAV9, suggesting a more favorable biodistribution profile for systemic or local AAV delivery in cancer. When this engineered AAV vector was used to deliver GRDC24, tumor growth was significantly suppressed in MPNST models, and a two-dose AAV treatment regimen further improved efficacy. In addition, the miniNF1 transgene delivered by the AAV system rescued Schwann cell differentiation in NF1-null iPSC-derived neural crest cells, further supporting the functionality of the therapeutic design. Overall, this work demonstrates that even for an oversized tumor suppressor gene like NF1, AAV-mediated gene replacement therapy can be made feasible through simultaneous optimization of both the AAV payload and the AAV capsid.

Intratumoral Gene Delivery of 4-1BBL Boosts IL-12-Triggered Anti-Glioblastoma Immunity
Lunavat et al. showed how AAV-mediated immunotherapy can amplify cytokine-driven anti-tumor responses in glioblastoma. The study began with the observation that recombinant IL-12 can stimulate anti-tumor immunity, but the authors hypothesized that a locally delivered AAV vector encoding 4-1BBL could sustain and strengthen this immune activation within the tumor microenvironment.

After optimizing recombinant IL-12 dosing, the group found that 50 ng provided the best balance between efficacy and tolerability. Mechanistic studies demonstrated that the effect depended on CD8+ T cells, while scRNA-seq identified Il12b-positive dendritic cells as important mediators of the response. To reinforce this pathway, the researchers used an AAVF capsid carrying a GFAP promoter-driven 4-1BBL transgene, creating an AAV immunotherapy vector designed to target GFAP-expressing cells in the glioblastoma microenvironment. This AAV-based strategy was evaluated in several syngeneic GB models, including CT-2A, GL261, and 005.

The combined AAV plus cytokine therapy produced markedly improved outcomes. Recombinant IL-12 alone extended median survival by 6 to 17 days but adding AAVF-GFAP-m4-1BBL further extended survival and produced 40–45% long-term survival in two glioblastoma models. Notably, the intratumoral AAV platform outperformed anti-PD-L1 therapy and did so without major systemic toxicity, as liver enzyme levels remained normal. The data suggests that AAV-mediated 4-1BBL delivery can act as a sustained local co-stimulatory reservoir, allowing AAV gene transfer to convert a transient cytokine signal into a more durable and effective anti-tumor immune response. This study is a strong example of how AAV in cancer can function not just as a gene delivery tool, but as a programmable immunotherapy platform.

Liver-Directed AAV-IL-10 Therapy Enhances CD8+ T Cell-Mediated Immunity Against Hepatocellular Carcinoma
Lin et al. investigated whether liver-directed AAV gene delivery of IL-10 could overcome the profoundly immunosuppressive liver environment in hepatocellular carcinoma. This work is particularly notable because it uses an AAV platform not for classical gene replacement, but for microenvironmental reprogramming within the liver.

To deliver IL-10, the authors used AAV-DJ, a hybrid AAV capsid with strong hepatocyte tropism. This AAV vector was tested in orthotopic and intrahepatic metastatic HCC models using Hep55.1c cells. To define the mechanism of action, the researchers performed CD8+ T-cell depletion studies and used FTY720 to distinguish liver-resident immune responses from those mediated by circulating cells. Flow cytometry was also used to characterize a Trm-like CD8+ T-cell population, allowing the team to understand how AAV-mediated IL-10 expression altered local immune architecture.

The results showed that AAV-IL-10 significantly reduced intrahepatic tumor burden and enhanced CD8+ T-cell infiltration and effector activity, including increased IFN-γ and granzyme B production. Importantly, the AAV-delivered IL-10 also expanded a liver-resident, self-sustaining Trm-like CD8+ T-cell population that persisted after tumor clearance. The effect remained liver-restricted, with no anti-tumor activity observed in distant subcutaneous tumors, reinforcing the idea that organ-targeted AAV delivery can produce highly localized immunological remodeling. This study positions AAV liver-directed cytokine therapy as a compelling strategy for HCC and highlights how AAV vectors can be used to build durable, tissue-specific immune memory against cancer.

Radiotherapy Synergizes with an Inducible AAV-Based Immunotherapy Platform
In a 2026 Cancer Cell paper, Marco et al. described that AAV-based cancer immunotherapy becomes mechanistically sophisticated and clinically strategic. The central insight was that radiotherapy enhances AAV-mediated tumor transduction, not by increasing vector uptake, but through epigenetic remodeling that makes the tumor more permissive to AAV transgene expression.

Studies showed that radiotherapy altered multiple chromatin regulators, including EZH2, HDAC2, CBP, and SWI/SNF components. The authors then built an inducible AAV immunotherapy vector carrying IL-12 under control of an IFN-responsive promoter (ISREx4), with 5x miR122T elements to reduce liver expression. This created a highly controlled AAV-iIL12 platform in which AAV-mediated cytokine expression would be preferentially activated in irradiated tumors. The system was tested across a broad range of tumor models, including colorectal, melanoma, lung, bladder, pancreatic, and glioblastoma models, and the immune consequences of the AAV treatment were characterized by scRNA-seq.

The therapeutic effect was dramatic. While AAV-iIL12 alone showed limited efficacy, combining radiotherapy with AAV-iIL12 resulted in complete tumor clearance in 100% of MC38 tumors and approximately 80% clearance in KPC and MB49 models. The AAV platform generated local IL-12 with minimal systemic leakage and no major toxicity, showing the value of spatially controlled AAV expression systems. The combination also remodeled the tumor microenvironment by increasing CD8+ T cells and inflammatory macrophages while reducing MDSCs and Tregs. This study strongly reinforces the idea that the future of AAV in cancer lies not only in better capsids, but also in smarter transcriptional control systems and rational combination strategies.

Synthetic Super-Enhancers Enable Precision Viral Immunotherapy
In a recent 2026 Nature study, Koeber et al. took AAV precision targeting to a new level by engineering synthetic super-enhancers (SSEs) that drive highly selective transgene expression in glioblastoma stem cells. Ther author also points out that AAV is a highly effective delivery vehicle for glioblastoma, characterized by six key attributes: (1) a small physical footprint that enhances interstitial distribution; (2) sustained transgene expression within quiescent cell populations; (3) minimal immunogenicity; and (4) a wide array of natural capsids for optimized transduction. Additionally, the platform is bolstered by (5) validated CNS delivery via convection-enhanced delivery (CED) and (6) a well-characterized manufacturing and regulatory safety profile. Rather than relying only on a tissue-specific promoter, the authors built a regulatory system designed specifically for precision AAV expression in a malignant cell state.

The team screened 4,579 enhancer-containing plasmids in glioblastoma stem cells and identified top-performing regulatory fragments, which were then assembled into multipart synthetic super-enhancers. Through ChIP-seq and EMSA, the authors showed that SOX2 and SOX9 co-bound strongly to SSE-7, forming higher-order transcription factor complexes that underpinned robust and selective activity. This SSE-7 regulatory element was then packaged into an AAV1 vector carrying a dual therapeutic payload, HSV-TK plus IL-12, creating a highly selective AAV immunotherapy construct. The vector was tested in a syngeneic glioblastoma model to evaluate both efficacy and tumor specificity.

The results demonstrated a powerful new model for AAV-based cancer targeting. SSE-7 drove expression at levels equal to or greater than the CMV promoter in glioblastoma stem cells, yet remained minimally active in fibroblasts, neurons, and microglia. In human GBM tissue slices, the AAV-SSE system showed strong activity in tumor tissue but restricted activity at normal brain margins. A single treatment with AAV1-SSE-7-HSV-TK-IL-12 produced curative outcomes in an aggressive glioblastoma model and induced long-term immunological memory that prevented recurrence. This study shows that next-generation AAV vectors can achieve not only tissue selectivity, but also cell-state selectivity, greatly expanding the precision and therapeutic potential of AAV in oncology.

Industry Update: Momentum in AAV-Based Cancer Therapies

AAV in cancer drug development is beginning to cross an important threshold from promising concept to early clinical reality. One important milestone is the advancement of AAV-based oncology therapies into human trials. In 2026, Siren Biotechnology received FDA clearance for what is believed to be the first Investigational New Drug (IND) application for an AAV-based cancer therapy, targeting recurrent high-grade glioma. This program uses an AAV vector to deliver immune-modulating cytokines directly into tumors, enabling localized and sustained immune activation, with the clinical study being led at UCSF by Nicholas Butowski, MD. This matters because it positions AAV oncology as a true clinical development category rather than a purely preclinical field.

What to Watch at AACR 2026: AAV in Cancer Research

The 2026 AACR meeting features high-impact abstracts that showcase AAV’s expanding versatility as both a modeling tool and a precision therapeutic modality. Among these, a few standout abstracts are particularly noteworthy.

Abstract 0278: In Vivo Adenine Base Editing of STK11 for Radiosensitization

Presenter: Jiazhuo Yan (Tianjin Medical University)

Summary: This study identifies STK11Q37* nonsense mutation as a driver of radiation resistance in NSCLC. Using a high-fidelity adenine base editor (A8E-N108Q-R26G) delivered via dual-AAV system, the authors achieved precise correction of the pathogenic mutation in patient-derived organoid xenografts. Corrected tumors showed restored LKB1 expression, reduced NRF2 activity, increased ROS levels upon irradiation, and significantly enhanced radiosensitivity.

Why it matters: This represents a precision gene editing approach to overcome a specific mechanism of therapy resistance, with direct translational potential for NSCLC patients carrying STK11 mutations.

Abstract 2852: Targeting Notch Signaling in TNBC with AAV-Notch1 Decoy

Presenter: Mrityunjoy Biswas (LSU Health New Orleans)

Summary: Notch signaling is critical for cancer stem cell maintenance in triple-negative breast cancer (TNBC), but gamma secretase inhibitors have failed clinically due to intestinal toxicity. The authors developed an rAAV vector encoding a soluble Notch1 decoy (rAAV-Notch1D) for intratumoral delivery. The decoy significantly reduced tumor growth in syngeneic TNBC models, increased CD3+ and CD8+ tumor-infiltrating lymphocytes, and enhanced the efficacy of anti-PD-1 immunotherapy.

Why it matters: This approach avoids systemic toxicity by local delivery and targets Notch signaling without affecting normal intestinal stem cells. RNA sequencing revealed upregulation of Hmox1, Timp3, Il33 and downregulation of Per1, identifying potential biomarkers and mechanisms.

Abstract 2176: Mutating E-cadherin in Rats to Model Invasive Lobular Breast Cancer

Presenter: Yuxiang Lin (Baylor College of Medicine)

Summary: Invasive lobular carcinoma (ILC) accounts for 8-14% of breast cancers and is almost always ER+. Existing mouse models rarely show estrogen dependence. Using intraductal delivery of AAV-sgRNA targeting Cdh1 and activating PIK3CAH1047R in Cas9-expressing rats, the authors generated tumors with latency of 2-3 months (vs. 4 months for PIK3CA alone). Tumors were ER+, PR+, hormone-dependent, and histologically consistent with ILC.

Why it matters: This is a clinically relevant, hormone-dependent rat model of ILC that recapitulates human disease biology, enabling studies of tumor evolution and therapeutic vulnerabilities that were previously impossible.

Abstract 4790: Cancer Reprograms the Remote Vascular Microenvironment

Presenter: Lingfeng Luo (Stanford University)

Summary: This study investigates how tumors remotely remodel the vasculature to promote atherosclerosis. Using bulk and single-cell RNA-seq of aortas from tumor-bearing mice, the authors identified a TNF-driven, LRG1-dependent endothelial pro-angiogenic pathway. Endothelial-targeted AAV-LRG1 knockdown reversed these changes. Human cohort data confirmed increased atherosclerotic CVD risk in cancer survivors.

Why it matters: While not a cancer therapy per se, this study uses AAV as a research tool to validate the TNF-LRG1 axis as a therapeutic target for mitigating cancer-induced cardiovascular toxicity—an important survivorship issue.

Author: Jin Qiu

Reference:

1. Bai et al., “Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors,” Nature Communications, 2025.
2. Marco et al., “Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity,” Cancer Cell, 2026.
3. Lunavat et al., “Intratumoral gene delivery of 4-1BBL boosts IL-12-triggered anti-glioblastoma immunity,” bioRxiv, 2025.
4. Zang et al., “Progress, Applications and Prospects of CRISPR-Based Genome Editing Technology in Gene Therapy for Cancer and Sickle Cell Disease,” Human Gene Therapy, 2024.
5. Yoo et al., “AAV for ovarian cancer gene therapy,” Cancer Gene Therapy, 2025.
6. Park et al., “Gene editing in cancer therapy: overcoming drug resistance and enhancing precision medicine,” Cancer Gene Therapy, 2025.
7. Lin et al., “Liver-directed AAV-IL-10 therapy enhances CD8+ T cell-mediated immunity against hepatocellular carcinoma,” Journal for Immunotherapy of Cancer, 2026.
8. Koeber et al., “Synthetic super-enhancers enable precision viral immunotherapy,” Nature, 2026.